Oncology Hematology Care, Incorporated

Cincinnati, Ohio 45242

2 studies enrolling now · 6 studies all time

What they study most

Extensive-Stage Small-Cell Lung Cancer, Metastatic Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer (NSCLC), Prostate Cancer, Relapsed or Refractory Multiple Myeloma, Small Cell Lung Carcinoma, Small-Cell Lung Cancer

Studies at this site

• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer — Recruiting now
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer — Recruiting now
• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab — Running, not enrolling
• Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet — Completed
• A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen — Completed
• Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone — Completed